Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00690313
Recruitment Status : Completed
First Posted : June 4, 2008
Last Update Posted : August 7, 2019
Sponsor:
Collaborator:
Alcon Research
Information provided by (Responsible Party):
Illinois Retina Associates

Brief Summary:

Antibiotic eye drops are being used before and after intravitreal injections. Currently there is no study indicating the benefit of there usage or their dosage.

In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior to the injection versus 1 day prior to intravitreal injection.


Condition or disease Intervention/treatment Phase
Intravitreal Injection Patients Drug: Vigamox Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection
Study Start Date : August 2008
Actual Primary Completion Date : April 2011
Actual Study Completion Date : April 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Arm 1
Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
Drug: Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection

Active Comparator: Arm 2
Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
Drug: Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection




Primary Outcome Measures :
  1. Timed study [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient who need intravitreal injections patients who are willing to participate in the study

Exclusion Criteria:

  • Patients who are allergic to Vigamox or who have taken any eye drops within the past 3 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00690313


Locations
Layout table for location information
United States, Illinois
Illinois Retina Associates
Harvey, Illinois, United States, 60426
Sponsors and Collaborators
Illinois Retina Associates
Alcon Research
Investigators
Layout table for investigator information
Principal Investigator: Kourous A Rezaei, MD Illinois Retina Associates SC

Layout table for additonal information
Responsible Party: Illinois Retina Associates
ClinicalTrials.gov Identifier: NCT00690313     History of Changes
Other Study ID Numbers: Vig508
First Posted: June 4, 2008    Key Record Dates
Last Update Posted: August 7, 2019
Last Verified: August 2019

Keywords provided by Illinois Retina Associates:
Vigamox, topical antibiotics, Intravitreal injections, macular degeneration, endophthalmitis

Additional relevant MeSH terms:
Layout table for MeSH terms
Moxifloxacin
Ophthalmic Solutions
Norgestimate, ethinyl estradiol drug combination
Pharmaceutical Solutions
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs